Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
Biopsy-based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.
Authors
- William M. Gallagher (ORCID: https://orcid.org/0000-0002-4307-5999)
- Debra F. Higgins (ORCID: https://orcid.org/0000-0002-3205-2409)
- Anders Bjartell (ORCID: https://orcid.org/0000-0002-5761-3786)
- Katherine M. Sheehan (ORCID: https://orcid.org/0000-0002-8969-3610)
- Agnieszka Krzyzanowska (ORCID: https://orcid.org/0000-0002-1288-7054)
- Leah McGuire
- Tony Loughman (ORCID: https://orcid.org/0000-0002-4632-7450)
- Chan‐Ju Angel Wang (ORCID: https://orcid.org/0000-0002-1529-7623)
- Stephen Barron
- R. William G. Watson (ORCID: https://orcid.org/0000-0001-8831-3244)
- Bozena Fender
- Joanna Fay (ORCID: https://orcid.org/0000-0001-6294-2886)
- Amanda O’Neill
- Des O'Leary
- Anthony O’Grady
Institutions
- University College Dublin (IE)
- Lund University (SE)
- Beaumont Hospital (IE)
- Novartis (Ireland) (IE)
Publication Details
- Journal
- BJUI Compass
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1002/bco2.474
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science Foundation Ireland
- Cancerfonden
- Vetenskapsrådet